Research Signal – Source date 2021-04-05
A tumor can contain immune cells that recognize cancer, yet that recognition alone does not ensure the cancer will shrink. Adoptive cell therapy tries to make more use of those cells: doctors collect tumor-infiltrating lymphocytes (TILs)—immune cells found inside a tumor—grow them outside the body, then return them to the patient. Some people with metastatic melanoma have had complete tumor regression after treatment. Many others do not respond, or respond and later become resistant.
A 2021 review traces this gap to several separate challenges. The tumor may become harder to recognize, the collected cells may be too few or poorly suited to persist, and conditions around the tumor can blunt their activity. The strongest numerical examples in the review come from metastatic melanoma studies, and their results belong to their own study settings rather than to solid cancers as a whole.
A patient’s own immune response becomes the starting material
TIL therapy begins with removal of tumor tissue. Immune cells are separated from the sample and grown in a laboratory. In some protocols, the expanded cells are tested against the patient’s own tumor cells; those that release interferon gamma, a sign of immune activation, are treated as tumor-reactive. The selected cells are then multiplied to make an infusion product and returned to the patient.
The approach is personalized because the starting cells come from that patient’s tumor and may already recognize features of it. Those features can include neoantigens, new protein fragments created by mutations in cancer cells. The therapy does not need to begin by choosing one target expected to be shared by every person with the same cancer type. Instead, it tries to expand an existing, patient-specific response.
Producing the cells takes time. In the review’s description of traditional selection and expansion, the process from tumor removal to administration typically takes six to eight weeks, and the infusion product commonly contains at least 10 billion cells. The review also describes “young” TIL approaches that shorten culture by using expanded cells without the same additional selection for tumor reactivity. These approaches were developed in part because longer time in culture was associated with shorter telomeres in the transferred cells, while longer telomeres were associated with clinical response. Such associations helped motivate a faster process; they do not show that culture time alone determines an individual patient’s outcome.
Recognition can break down inside the tumor
Even a large infusion of tumor-reactive cells faces a changing target. Cancers accumulate mutations, and different tumors—even of the same type—can differ in their mutations and surrounding tissue. Tumors with more mutations have more chances to produce neoantigens that T cells can recognize. But when T cells destroy cells carrying a recognizable target, cancer cells without that target may survive and grow. A tumor can also reduce major histocompatibility complex (MHC) molecules or other parts of antigen presentation, the process that displays a target for immune recognition.
Access and local conditions matter too. Dense tissue, signals that repel immune cells, or abnormal blood vessels can make it harder for infused cells to enter the tumor. Once there, T cells may encounter regulatory T cells and myeloid-derived suppressor cells, which can dampen immune activity. These cells can release suppressive signals, use up nutrients T cells need, or interfere with other immune cells. Repeated inhibitory signaling, including through PD-1 and CTLA-4 checkpoints, can leave T cells exhausted: less able to multiply and carry out their tumor-killing functions.
Resistance may be present from the start or emerge after an initial response. In either case, the result can be a shortage of functional tumor-directed T cells or suppression of cells that could otherwise act. Blocking checkpoint signals is one strategy the review discusses for restoring activity, but the surrounding tumor environment can contain several barriers at once.
More cells are useful only if they can keep working
The number and character of the infusion product are related but distinct questions. Studies summarized in the review associated objective responses with higher total TIL counts and, in particular, more CD8-positive T cells. Tumor samples with low lymphocyte infiltration were less likely to yield enough cells for reinfusion. Those observations point to a practical constraint before treatment even begins: some tumors may not provide enough starting material for a usable product.
After infusion, the cells also need to remain in the body and retain useful functions. In one study summarized by the review, tumor-specific T cells could still be detected in the blood of responding patients for as long as 34 months. Other reported analyses associated longer-lived tumor-specific cell populations with stronger responses. These findings describe patterns among patients; they do not establish that persistence by itself causes a response.
The type of cell may influence that staying power. In the studies discussed, CD8-positive T cells at an earlier stage of development were better able to multiply and carry out tumor-killing functions than more mature cells. The review describes early evidence that persistent cells carried features associated with less differentiated states. Selecting cells with those qualities may help address a different problem from simply increasing the total cell count: maintaining an effective population after it reaches the patient.
Preparation and immune support carry a safety cost
TIL infusion is part of a treatment sequence. In the protocols reviewed, chemotherapy first reduces the patient’s existing immune cells, a step called lymphodepletion; high-dose interleukin-2 (IL-2) has also been used after infusion to support the returned cells’ growth. The review describes evidence associating more intensive lymphodepletion with higher response rates in metastatic melanoma studies. In one comparison, adding 2 or 12 gray of total-body irradiation to chemotherapy was associated with response rates of 52% and 72%, respectively, compared with 49% for chemotherapy alone. These were separate patient groups within a reported clinical study, and greater intensity came with substantial treatment-related toxicity; many patients required advanced medical support.
High-dose IL-2 can also cause serious adverse effects, including vascular leak syndrome and neurological symptoms, and many patients could not complete the planned regimen. Lower-dose schedules were better tolerated in the studies reviewed. A pooled analysis estimated objective response rates of 43% with high-dose IL-2 and 35% with low-dose IL-2, with complete response estimates of 14% and 7%, respectively. These pooled figures combine different studies; the review notes that enrollment was limited and that a clinical trial directly comparing the two IL-2 approaches with TIL therapy had not been conducted. The apparent tolerability advantage therefore sits alongside uncertainty about how the regimens compare in effectiveness.
More tumor entry did not settle the combination question
The review also discusses combining TIL therapy with targeted treatment. About half of melanomas carry particular BRAF mutations, which can be treated with BRAF inhibitors. In preclinical work, BRAF inhibition was linked to greater T-cell entry into tumors and increased antigen presentation. A small clinical study tested a schedule that included vemurafenib around tumor removal and TIL infusion. The combination group had an objective response rate of 64% among 11 patients, while the TIL-only group had a rate of 60% among 15 patients.
Tumors sampled after combination treatment showed increased T-cell infiltration compared with TIL therapy alone, an encouraging biological observation. The response figures, however, do not demonstrate a patient benefit from adding the inhibitor: the groups were small, and the comparison does not establish that the combination improved outcomes. The example shows why a change inside the tumor and a meaningful difference for patients are related but separate measures.
Cell production shapes who can receive the treatment
The treatment’s demands extend beyond biology. Growing a personalized product is labor-intensive, fresh-cell schedules can be difficult to coordinate, and clinicians need the capacity to manage serious adverse events. The review describes TIL therapy as concentrated in large academic medical centers with the expertise and support systems required for production and care.
One proposed route to wider delivery was centralized manufacturing. In the model described, a medical center sends a surgically removed tumor to a dedicated facility, which expands and cryopreserves the TIL product before returning it for treatment. Central production could reduce the need for each hospital to build its own cell-growing operation and make scheduling more flexible than relying on fresh cells. It still depends on tumor removal, transport, specialist treatment, and appropriate medical monitoring, so the model itself does not establish broad access.
What could bring this therapy beyond specialist centers
If cell production becomes more reliable and easier to coordinate, and if treatment teams can manage its risks, more patients may be able to receive an approach built from immune cells already present in their tumors. For some, that could mean a chance at durable regression in advanced disease. Reaching that possibility depends on overcoming both biological resistance and the practical demands of manufacturing and care; the melanoma experience described in the 2021 review does not show that the same benefit will extend across solid cancers.
Key Sources
- Primary source: Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care.
DOI or Journal Page · Review or Meta-Analysis · 2021-04-05
Keep exploring